<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134486">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01910779</url>
  </required_header>
  <id_info>
    <org_study_id>18/04/13</org_study_id>
    <nct_id>NCT01910779</nct_id>
  </id_info>
  <brief_title>Optimization of Initial Energy for Cardioversion of Atrial Fibrillation With Biphasic Shocks</brief_title>
  <acronym>OPTIMA</acronym>
  <official_title>Optimization of Initial Energy for Cardioversion of Atrial Fibrillation With Biphasic Shocks (OPTIMA Trial).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maria Vittoria Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maria Vittoria Hospital</source>
  <oversight_info>
    <authority>Italy: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Use of higher energy doses (120-150 J) may not offer additional benefits and higher success
      rate compared with low to moderate initial energy (100-120 J) of biphasic shock for atrial
      fibrillation cardioversion. In this prospective open-label randomized trial consecutive
      patients with AF and candidate to AF electrical cardioversion will be randomized to receive
      100J or 120 J as initial dose of biphasic shock. Patients will be also randomized in each
      group to anterolateral or postero-anteriore placement of defibrillator electrodes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open-label randomized trial to assess the efficacy of alternative initial biphasic shocks
      (100 versus 120 J) for cardioversion of atrial fibrillation including alternative option for
      electrode placement (anterolateral or postero-anterior in each group).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Electrical cardioversion success</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Electrical cardioversion success</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications rate</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">154</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Cardioversion</condition>
  <arm_group>
    <arm_group_label>100 joule arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 joule as first biphasic shock energy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>120 joule arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>120 joule as first biphasic shock energy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>100 joule as first biphasic shock energy</intervention_name>
    <arm_group_label>100 joule arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>120 joule as first biphasic shock energy</intervention_name>
    <arm_group_label>120 joule arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult (Age&gt;18 years)

          -  Candidate to Cardioversion for recent onset, persistent atrial fibrillation (&gt;48
             hours but &lt; 12 months)

          -  Informed Consent

        Exclusion Criteria:

          -  Atrial Flutter or other arrythmias
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Massimo Imazio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiology Dpt. Maria Vittoria Hospital, Torino, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Massimo Imazio, MD</last_name>
    <phone>+39011439</phone>
    <phone_ext>3391</phone_ext>
    <email>massimo_imazio@yahoo.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cardiology Dpt. Maria Vittoria Hospital</name>
      <address>
        <city>Torino</city>
        <zip>10141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Massimo Imazio, MD</last_name>
      <phone>+39011439</phone>
      <phone_ext>3391</phone_ext>
      <email>massimo_imazio@yahoo.it</email>
    </contact>
    <investigator>
      <last_name>Massimo Imazio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Massimo Giammaria, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mara Carraro</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 29, 2013</lastchanged_date>
  <firstreceived_date>July 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maria Vittoria Hospital</investigator_affiliation>
    <investigator_full_name>Massimo Imazio</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Cardioversion</keyword>
  <keyword>Biphasic Shock</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
